Insulet Stock Today
| PODD Stock | USD 255.44 10.77 4.40% |
PerformanceVery Weak
| Odds Of DistressVery Small
|
Insulet is trading at 255.44 as of the 16th of March 2025, a 4.40% increase since the beginning of the trading day. The stock's lowest day price was 246.5. Insulet has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on April 19, 2024, Senator Tina Smith of US Senate acquired $50k to $100k worth of Insulet's common stock.
Business Domain Health Care Equipment & Services | IPO Date 15th of May 2007 | Category Healthcare | Classification Health Care |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 70.23 M outstanding shares of which 2.16 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover. More on Insulet
Moving against Insulet Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Insulet Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | James Hollingshead | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP 500 Index, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Baby Boomer Prospects, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInsulet can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Insulet's financial leverage. It provides some insight into what part of Insulet's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insulet (PODD) is traded on NASDAQ Exchange in USA. It is located in 100 Nagog Park, Acton, MA, United States, 01720 and employs 3,900 people. Insulet is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 17.94 B. Insulet conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 70.23 M outstanding shares of which 2.16 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover.
Insulet currently holds about 708.6 M in cash with 430.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.21.
Check Insulet Probability Of Bankruptcy
Ownership AllocationThe majority of Insulet outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Insulet to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Insulet. Please pay attention to any change in the institutional holdings of Insulet as this could imply that something significant has changed or is about to change at the company. On April 19, 2024, Senator Tina Smith of US Senate acquired $50k to $100k worth of Insulet's common stock.
Check Insulet Ownership Details
Insulet Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Amvescap Plc. | 2024-12-31 | 1.2 M | |
| Groupama Asset Management | 2024-12-31 | 1.1 M | |
| Norges Bank | 2024-12-31 | 953 K | |
| American Century Companies Inc | 2024-12-31 | 854.9 K | |
| Artisan Partners Limited Partnership | 2024-12-31 | 770.2 K | |
| Northern Trust Corp | 2024-12-31 | 738.8 K | |
| Citadel Advisors Llc | 2024-12-31 | 729.1 K | |
| Macquarie Group Ltd | 2024-12-31 | 691 K | |
| William Blair Investment Management, Llc | 2024-12-31 | 676.3 K | |
| Vanguard Group Inc | 2024-12-31 | 8.5 M | |
| Fmr Inc | 2024-12-31 | 7.8 M |
Insulet Historical Income Statement
Insulet Stock Against Markets
Insulet Corporate Management
| Philip Hildale | Senior Care | Profile | |
| Andrew Isaacson | Senior Development | Profile | |
| Prem Singh | Senior Operations | Profile | |
| Laetitia Cousin | Quality Affairs | Profile | |
| John JD | Senior Counsel | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 5.77 | Revenue Per Share | Quarterly Revenue Growth 0.172 | Return On Assets |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.